Beta-thalassemia major management has advanced remarkably over the past four decades - transforming a historically fatal condition into one where patients routinely live into adulthood with careful multidisciplinary care.
1. Transfusion Support #
Regular red-cell transfusion (every 2-4 weeks) to maintain hemoglobin ~9-10.5 g/dL is the foundational therapy, preventing anemia-related morbidity and suppressing ineffective erythropoiesis.
2. Iron Chelation #
Transfusion brings iron overload - inevitable without chelation. Deferasirox (once-daily oral, dispersible or film-coated) is the standard; deferiprone and deferoxamine are alternatives for specific situations. Dose is weight-based and titrated against ferritin, LIC and tolerability.
3. Curative Options #
- Allogeneic haematopoietic stem-cell transplantation (HSCT) - curative in younger patients with HLA-matched donors and minimal iron-related organ damage
- Gene therapy / gene editing - emerging modalities (e.g. beta-globin gene addition, BCL11A disruption) available in select centres; expanding over time
4. Supportive Care #
- Endocrine replacement where required (thyroid, gonadal, diabetes management)
- Osteoporosis prevention and management
- Cardiac monitoring and intervention
- Psychosocial support and adherence counselling
- Splenectomy in selected cases (now less frequent)
5. Public-Health Perspective #
In high-prevalence regions (Mediterranean, Middle East, South Asia, Southeast Asia), reliable access to transfusion, chelation and monitoring is a public-health priority. DEFRATAJ supplies WHO-GMP Deferasirox across these regions - see thalassemia page for detail.